Home patients
 

Keywords :   


Tag: patients

Mercks Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection

2014-04-11 07:00:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. Clinical Findings Support Initiation of C-EDGE Phase 3 Program WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced interim results from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection (GT1). Language: English Contact: MerckMedia Contacts:Caroline Lappetito, 267-305-7639Sarra Herzog, 201-669-6570orInvestor Contacts:Carol Ferguson, 908-500-1101Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: activity combination patients therapy

 

Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Nave Patients with Genotype 1 Infection

2014-04-10 07:00:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. Clinical Findings Support Advancement into Phase 3 Trials WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced additional data from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of a once-daily, all-oral regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection (GT1). Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639Sarra Herzog, 201-669-6570orInvestors:Carol Ferguson, 908-500-1101Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with results studies patients

 
 

AB SCIEX Announces Immunosuppressants Kit For Use By Doctors In Europe To Help Care For Organ Transplant Patients

2014-04-02 10:16:06| drugdiscoveryonline Home Page

Every organ transplant patient in the world faces the potential danger of his/her body rejecting a new organ, such as a heart, kidney or liver. Immunosuppressant drugs are required to help prevent rejection

Tags: care europe kit patients

 

First Austrian Cancer Patients Receive Treatments on Advanced Elekta Versa HD Radiation ...

2014-04-02 06:00:00| Industrial Newsroom - All News for Today

In complex cases, Medical University Innsbruck clinicians exploit speed and accuracy advantages of new groundbreaking linear accelerator<br /> <br /> INNSBRUCK, Austria &ndash; Medical University Innsbruck is the first center in Austria to begin treating patients with Elekta's Versa HD&trade;, a radiation therapy system equipped with advanced beam-shaping and high dose rate technologies to deliver extremely precise treatments in shorter treatment times. Since January 14, the clinic has put 55 ...This story is related to the following:Automatic IDSearch for suppliers of: Radio Frequency Identification (RFID) Systems |

Tags: advanced receive cancer patients

 

Surgical Drapes ensure safety of staff and patients.

2014-04-01 14:31:18| Industrial Newsroom - All News for Today

Ranging from absorbent to repellent, TrustShield&trade; Single-Use Surgical Drapes deliver maximum protection. Impervious and absorbent drapes made from laminate fabrics are designed for most demanding surgeries creating total barrier to bacteria and viruses. Repellent SMS spunbond-meltblown-spunbond fabrics are designed for low-risk surgeries where minimal amounts of fluid are present. This story is related to the following:Surgical Drapes

Tags: staff safety ensure patients

 

Sites : [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] next »